Published in:
01-10-2019 | Crohn's Disease | Original Article
Association Between Cannabis Use and Complications Related to Crohn’s Disease: A Retrospective Cohort Study
Authors:
Chimezie Mbachi, Bashar Attar, Yuchen Wang, Isaac Paintsil, Benjamin Mba, Setri Fugar, Rohit Agrawal, Roberto Carlos Simons-Linares, Palash Jaiswal, William Trick, Vikram Kotwal
Published in:
Digestive Diseases and Sciences
|
Issue 10/2019
Login to get access
Abstract
Background
Crohn’s disease is an idiopathic inflammatory process that is occasionally associated with complications, which cause significant morbidity and mortality. The anti-inflammatory effect of cannabis in intestinal inflammation has been shown in several experimental models; it is unknown whether this correlates with fewer complications in Crohn’s disease patients.
Aims
To compare the prevalence of Crohn’s disease-related complications among cannabis users and non-users in patients admitted with a primary diagnosis of Crohn’s disease or a primary diagnosis of Crohn’s related complication and a secondary diagnosis of Crohn’s disease between 2012 and 2014.
Methods
We used data from the Healthcare Cost and Utilization Project–National Inpatient Sample. Cannabis users (615) were compared directly after propensity score match to non-users, in aspects of various complications and clinical end-points.
Results
Among matched cohorts, Cannabis users were less likely to have the following: active fistulizing disease and intra-abdominal abscess (11.5% vs. 15.9%; aOR 0.68 [0.49 to 0.94], p = 0.025), blood product transfusion (5.0% vs. 8.0%; aOR 0.48 [0.30 to 0.79], p = 0.037), colectomy (3.7% vs. 7.5%; aOR 0.48 [0.29–0.80], p = 0.004), and parenteral nutrition requirement (3.4% vs. 6.7%, aOR 0.39 [0.23 to 0.68], p = 0.009).
Conclusion
Cannabis use may mitigate several of the well-described complications of Crohn’s disease among hospital inpatients. These effects could possibly be through the effect of cannabis in the endocannabinoid system.